Cited 20 times in
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2018-09-28T08:59:06Z | - |
dc.date.available | 2018-09-28T08:59:06Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/163301 | - |
dc.description.abstract | OBJECTIVES: We aimed to investigate the clinical characteristics of lung adenocarcinomas with acquired EGFR T790M mutation focusing on brain metastasis and survival. MATERIALS AND METHODS: Our study included patients who had lung adenocarcinoma harboring EGFR mutation at 1st biopsy and then underwent 2nd biopsy after resistance to first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Statistical analyses were performed to examine the associations between clinicopathologic features of lung adenocarcinoma and presence of acquired T790M mutation. RESULTS: A total of 111 patients were identified. Of these, 58 patients (52.3%) had acquired T790M mutations. Osimertinib was used in 29 patients (26.1%) after resistance to first- or second-generation TKIs. The T790M mutation was more frequently found in patients with exon 19 deletion than in those with L858R mutations (p = .026) and in patients who had longer treatment duration with EGFR-TKI (p = .0398). Multivariate analysis revealed that exon 19 deletion (p = .003) were independently associated with T790M mutation. Patients with acquired T790M mutation showed a longer progression-free survival. In addition, patients who had T790M mutation or who received osimertinib treatment had a longer overall and post-progression survival than patients who did not. Brain metastasis-free survival was also longer in the T790M-positive group or osimertinib-treated group among patients who had no brain metastasis at the time of diagnosis. Osimertinib treatment was independently associated with longer overall, post-progression, and brain metastasis-free survival. CONCLUSION: The status of acquired T790M mutation was correlated with exon 19 deletion and longer progression-free survival to first- or second-generation EGFR-TKIs. A third-generation EGFR-TKI, osimertinib, was strongly associated with brain metastasis-free survival as well as other survival indicators in patients with EGFR-mutant lung adenocarcinoma. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Jin Woo Joo | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.identifier.doi | 10.1016/j.lungcan.2018.04.013 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 29858020 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0169500218303416 | - |
dc.subject.keyword | Brain metastasis | - |
dc.subject.keyword | Drug resistance | - |
dc.subject.keyword | EGFR | - |
dc.subject.keyword | Lung cancer | - |
dc.subject.keyword | Osimertinib | - |
dc.subject.keyword | Survival | - |
dc.subject.keyword | T790M | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Hong, Min Hee | - |
dc.citation.volume | 121 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 17 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.121 : 12-17, 2018 | - |
dc.identifier.rimsid | 58565 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.